Delivery Order SPE2DX22D0010-SPE2D826FAB73
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $13,562.15 to AmerisourceBergen Drug Corp for Vyvanse 50mg capsules. This firm fixed-price contract, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a competitively awarded non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse (lisdexamfetamine) 10mg capsules, with a ceiling value of $1,085.13. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by October 1, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will fulfill this order from its corporate office location. This delivery order...
- The Defense Logistics Agency's Medical Supply Chain awarded a $17,094.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Vyvanse capsules 50mg, with completion targeted for September 15, 2025. This non-set-aside delivery order represents a routine pharmaceutical procurement under AmerisourceBergen's existing contract vehicle and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen is a...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse (lisdexamfetamine) 30mg capsules under a firm fixed-price contract with a ceiling value of $30,816.60. This delivery order, awarded on September 15, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical. The award was competitively awarded with no set-aside designation...
- The Defense Logistics Agency awarded a $6,017.62 delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Vyvanse 50 mg capsules (100-count units). This is a firm fixed price, non-set-aside contract with a completion date of September 25, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $2,943.88. This is a non-set-aside competitive award with a place of performance in Conshohocken, Pennsylvania, and an ultimate completion date of August 7, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $2,565.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,066.12 and an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Vyvanse capsules 60mg, with a ceiling value of $7,226.08 and a firm fixed price structure. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract will be performed at...
- SPE2DX22D0010Indefinite Delivery Contract
- SPE2DX22D0010-SPE2D826FAB73Delivery Order
The Department of Defense's Medical Supply Chain awarded a $26,751.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (50mg) on October 3, 2025, with an ultimate completion date of October 6, 2025. This non-compete, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a significant federal procurement portfolio supplying comprehensive pharmaceutical products and medical supplies to military and veteran healthcare systems. The company's extensive experience fulfilling federal medical requirements through the DLA's Pharmaceutical Prime Vendor Global Program demonstrates its capability to meet defense healthcare needs across multiple therapeutic domains. This delivery order for Vyvanse, a prescription medication used in the treatment of attention-deficit/hyperactivity disorder and binge eating disorder, reflects the ongoing pharmaceutical supply demands of the federal defense medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.8k | 10/3/25 |